Ani Pharmaceuticals Inc. (ANIP)
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ANI Pharmaceuticals: Worthy Of A Position
ANI Pharmaceuticals recently offered up solid FY26 guidance with 15% non-GAAP EPS growth and strong momentum from Cortrophin Gel. ANIP's increasing reliance on Cortrophin Gel, projected to reach 52% of FY26 revenue, is offset by patent protection and a complex formulation. The company's balance sheet remains solid, supporting ongoing investments in rare disease expansion and 10–15 annual generic launches.
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Can ANI (ANIP) Climb 43.86% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for ANI (ANIP) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease
ANIP eyes 2026 pivot as Rare Disease targets 60% of sales, with Cortrophin growth, gout sales force expansion, and retina rebound shaping momentum.
Is ANIP Undervalued? How to Read Its 9.3x Forward P/E
ANI Pharmaceuticals ANIP has shifted into a specialty-led growth story, with Cortrophin Gel now the main engine and the retina franchise positioned for a reset and recovery. At the same time, the stock's valuation has compressed to levels that stand out against peers and the broader market.
ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset
ANI Pharmaceuticals' growth pivots to Cortrophin Gel as retina headwinds weigh on 2025, with 2026 recovery hopes hinging on specialty momentum and portfolio reset.
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts See a 44.84% Upside in ANI (ANIP): Can the Stock Really Move This High?
The mean of analysts' price targets for ANI (ANIP) points to a 44.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ANI Pharmaceuticals, Inc. (ANIP) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (ANIP) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.
ANI Pharmaceuticals Q4 2025: Strong Growth, But Execution Risks Emerge
ANI Pharmaceuticals delivered strong Q4 and FY25 results, with revenue up 30% and record Cortrophin Gel growth. I see near-term risks from seasonally weaker Cortrophin sales due to insurance reverifications and delayed impact from the expanded gout sales force. Management reaffirmed 2026 guidance for $1.06-$1.12B revenue and up to $290M adjusted EBITDA, but execution and timing risks remain.
